Skip to main content
. 2019 Aug 14;9:771. doi: 10.3389/fonc.2019.00771

Table 1.

Clinical and histopathologic characteristics of patients.

Characteristics SEER Cohort
(2006–2015) (n = 124,788)
FDZSH Cohort
(2009–2014) (n = 1,675)
PKUPH Cohort
(2000–2017) (n = 2,572)
Gender
  Male 64,448 (51.6) 918 (54.8) 1,391 (54.1)
  Female 60,340 (48.4) 757 (45.2) 1,181 (45.9)
Age, years
  <65 46,348 (37.1) 1,149 (68.6) 1,471 (57.2)
  ≥65 78,440 (62.9) 526 (31.4) 1,101 (42.8)
Location
  Upper lobe 75,130 (60.2) 882 (52.7) 1,313 (51.0)
  Middle lobe 5,888 (4.7) 114 (6.8) 174 (6.8)
  Lower lobe 37,072 (29.7) 518 (30.9) 763 (29.7)
  Overlapping lesion of lung 1,396 (1.1) 155 (9.2) 133 (5.2)
  Unknown 5,302 (4.3) 6 (0.4) 189 (7.3)
Histology
  Squamous cell carcinoma 42,380 (34.0) 434 (25.9) 497 (19.3)
  Adenocarcinoma 82,408 (66.0) 1,241 (74.1) 2,075 (80.7)
Grade
  Well-differentiated; Grade I 9,730 (7.8) 34 (2.0) 105 (4.1)
  Moderately differentiated; Grade II 32,599 (26.1) 751 (44.8) 1,222 (47.5)
  Poorly differentiated; Grade III 37,182 (29.8) 626 (37.4) 859 (33.4)
  Undifferentiated; anaplastic; Grade IV 1,023 (0.8) 264 (15.8) 386 (15.0)
  Unknown 44,254 (35.5)
8th AJCC/UICC stage
  I 34,259 (27.5) 985 (58.8) 1,644 (63.9)
  II 14,720 (11.8) 304 (18.1) 360 (14.0)
  III 27,190 (21.8) 372 (22.2) 484 (18.8)
  IV 48,619 (38.9) 14 (0.9) 84 (3.3)
Modified 8th stage
  I 33,803 (27.1) 994 (59.4) 1,614 (62.8)
  II 28,048 (22.5) 535 (31.9) 704 (27.4)
  III 25,647 (20.6) 139 (8.3) 188 (7.3)
  IV 37,290 (29.8) 7 (0.4) 66 (2.5)
Treatment
  Surgery 44,194 (35.4) 1,675 (100) 2,572 (100)
  No surgery 80,312 (64.4)
  Unknown 282 (0.2)